Toggle menu


Start date:
January 2014
End date:
July 2015
Co-ordinated by:
University of Edinburgh & NHS Lothian

Early Prediction of Severe Sepsis


To derive a biomarker to allow the identification of patients with confirmed sepsis, and risk stratify patients at risk of developing severe sepsis

Trial Design

A Prospective, multi-centre cohort observational study

Chief Investigator

Professor Tim Walsh, Critical Care Research Group

Local PI

Professor Tim Walsh

Research Team

  • EMERGE Research team
  • Critical Care Research Group
  • Rossi Lab, MRC Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh

Eligibility criteria (summary)

Patients who present to the Emergency Department with suspected sepsis

Further information

Research Team

Dr Deepankar Datta

Specialist Trainee Emergency Medicine

Julia Grahamslaw

Lead Research Nurse

Related news

Dip Dazzles at RCEM

Dip Dazzles at RCEM

9 Oct 2015 | Rachel O'Brien

Read more

More EMERGE Trials

1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.

Read more

RAMPP trial

RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax

Evaluating the kinetics of cardiac biomarkers after ST-segment Elevation myocardial infarction

Read more

HighSTEACS Bioresource

This trial is a two arm, multicentre parallel group, randomised controlled, open label trial comparing intravenous levetiracetam to intravenous phenytoin for the treatment of convulsive status epilepticus (CSE) in children, young people and young adults.

Read more


Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial